Clinical Trial

Feasibility Study of Induction and Maintenance Avelumab Plus R-CHOP in Patients With Diffuse DLBCL: The AvR-CHOP Study

Study acronym: AvR-CHOP
Unknown Early Phase 1
View on ClinicalTrials.gov →
Summary
To evaluate the feasibility of adding induction and maintenance Avelumab to the standard combination of R-CHOP in patients with stage II, III and IV diffuse large B cell lymphoma (DLBCL)
Protocol Amendment History 1 change
critical Trial status changed: Active, Not Recruiting → Unknown 2026-08-02
Trial Details
NCT Number NCT03244176
Lead Sponsor Austin Health
Collaborators: Merck KGaA, Darmstadt, Germany
Conditions Lymphomas Non-Hodgkin's B-Cell
Enrollment 28 participants
Start Date 2017-07-21
Primary Completion 2022-06-16 (estimated)
Study Completion 2025-07 (estimated)
Updated on ClinicalTrials.gov 2024-07-30